XML 33 R13.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Restructuring Charges | 12 Months Ended
--- | ---
Dec. 31, 2017
Restructuring And Related Activities [Abstract] |
Restructuring Charges | 7. Restructuring Charges On December 19, 2016, the Board of Directors approved a restructuring of its business based on its decision to focus the Company’s efforts on clinical development, with an initial focus on the X358 clinical programs. The restructuring included a reduction-in-force in which the Company terminated 57 employees (the “2016 Restructuring”). In addition, effective December 21, 2016, the Company’s Chief Executive Officer retired from his position. In early 2017, the Company further revised its business model to prioritize out-licensing activities, further curtail research and development spending, and terminated five additional employees (the “2017 Restructuring”). During the year ended December 31, 2017, the Company recorded charges of $3.4 million related to severance, other termination benefits and outplacement services in connection with the workforce reduction resulting from the 2017 Restructuring and 2016 Restructuring activities. During the year ended December 31, 2016, the Company recorded charges of $3.8 million related to severance, other termination benefits and outplacement services in connection with the workforce reduction resulting from the 2016 Restructuring. The Company recognized $0.6 million of non-cash stock-based compensation as a result of the acceleration of a former executive’s options and RSUs under his retention benefit agreement in 2016. In addition, in 2016, the Company recognized an asset impairment charge of $0.2 million related to leasehold improvements. On July 22, 2015, the Company announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet’s disease uveitis, run by Servier, did not meet the primary endpoint of increased time to first acute ocular exacerbation. Due to the results and the Company’s belief they would be predictive of results in its other EYEGUARD studies, in August 2015, the Company announced its intention to end the EYEGUARD global Phase 3 program. On August 21, 2015, the Company, in connection with its efforts to lower operating expenses and preserve capital while continuing to focus on its endocrine product pipeline, implemented a restructuring plan (the “2015 Restructuring”) that included a workforce reduction resulting in the termination of 52 employees during the second half of 2015. During the years ended December 31, 2016 and 2015, the Company recorded a credit of $32,000 and a charge of $2.9 million, respectively, related to severance, other termination benefits and outplacement services in connection with the workforce reduction resulting from the 2015 Restructuring. In addition, the Company recognized additional restructuring charges of $29,000 and $0.8 million in contract termination costs in 2016 and 2015, respectively, which primarily include costs in connection with the discontinuation of the EYEGUARD studies. The outstanding restructuring liabilities are included in accrued and other liabilities on the consolidated balance sheets. As of December 31, 2017 and 2016, the components of these liabilities are shown below (in thousands):
|  | Employee Severance |  |  | Contract |  |  |  |  |  |  |  |  |  |  |  |
|  | and Other Benefits |  |  | Termination Costs |  |  | Stock-based Compensation |  |  | Asset Impairment |  | Total |
Balance at December 31, 2015 |  | $ | 343 |  |  | $ | 116 |  |  | $ | — |  |  | $ | — |  | $ | 459 |
Restructuring charges |  |  | 3,720 |  |  |  | 29 |  |  |  | 619 |  |  |  | 198 |  |  | 4,566 |
Non-cash charges |  |  | — |  |  |  | — |  |  |  | (619 | ) |  |  | (198 | ) |  | (817 | )
Cash payments |  |  | (469 | ) |  |  | (145 | ) |  | — |  |  | — |  |  | (614 | )
Balance at December 31, 2016 |  |  | 3,594 |  |  |  | — |  |  |  | — |  |  |  | — |  |  | 3,594 |
Restructuring charges |  |  | 3,447 |  |  |  | — |  |  |  | — |  |  |  | — |  |  | 3,447 |
Cash payments |  |  | (6,911 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  | (6,911 | )
Balance at December 31, 2017 |  | $ | 130 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  | $ | 130 |
The Company expects to pay the remaining $0.1 million in 2018.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -URI http://asc.fasb.org/topic&trid=2175745 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration